(+)-JQ-1 - CAS 1268524-70-4

Catalog Number Size Price Stock Quantity
BP-300021 50 mg $199 In stock
Add to cart

(+)-JQ-1 is a potent and selective BET bromodomain inhibitor, IC50 values are 77 nM and 33 nM for inhibiting BRD4 (N-terminal) and BRD4 (C-terminal), respectively.

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Molecular Formula
Molecular Weight


    • Specification
      • Solubility
        In DMSO: ≥ 45 mg/mL (98.47 mM)
        * "≥" means soluble, but saturation unknown.
        White solid
        Shelf Life
        2 years
        Powder, -20°C, 3 years; 4°C, 2 years; In solvent, -80°C, 6 months; -20°C, 1 month
        Room temperature in continental US; may vary elsewhere.
        IUPAC Name
        tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate
    • Properties
      • Density
        1.33±0.1 g/cm3
        InChI Key
        Canonical SMILES
        Pub Chem ID
    • Reference Reading
      • 1. JQ-1 ameliorates schistosomiasis liver fibrosis by suppressing JAK2 and STAT3 activation
        Xinran Wang, Miao Liu, Yongsheng Ji, Cuiping Ren, Han Ding, Jijia Shen, Xuhan Yang, Jiaming Tian, Saeed El-Ashram Biomed Pharmacother . 2021 Dec;144:112281. doi: 10.1016/j.biopha.2021.112281.
        Schistosomiasis is a serious parasitic infection caused by Schistosoma. The parasite deposits eggs in the host liver, causing inflammation that activates hepatic stellate cells (HSCs), which leads to liver fibrosis. Currently, there is no effective therapy for liver fibrosis; thus, treatments are urgently needed. Therefore, in the present study, mice infected with Schistosoma japonicum were treated with JQ-1, a small-molecule bromodomain inhibitor with reliable anti-tumor and anti-inflammatory activities. The fibrotic area of the liver measured by computer-assisted morphometric analysis and the expression levels of the cytoskeletal protein alpha smooth muscle actin (α-SMA) and of collagen assessed by quantitative PCR, Western blot and immunohistochemistry were significantly decreased in the liver following JQ-1 treatment compared with vehicle-treated controls. Total RNA was extracted from the liver of JQ-1-treated Schistosoma-infected mice for RNA-sequencing analysis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses indicated that JQ-1 affected biological processes and the expression of cellular components known to play key roles in the transdifferentiation of HSCs to myofibroblasts. In vitro treatment with JQ-1 of JS-1 cells, a mouse HSC line, indicated that JQ-1 significantly inhibited JS-1 proliferation but had no effect on JS-1 activity, senescence, or apoptosis. Western blot results showed that JQ-1 inhibited the expression levels of phosphorylated JAK2 and phosphorylated STAT3 without altering expression levels of these non-phosphorylated proteins. Taken together, these findings suggested that JQ-1 treatment ameliorated S. japonicum egg-induced liver fibrosis, at least in part, by suppressing HSC activation and proliferation through the inhibition of JAK2/STAT3 signaling. These results lay a foundation for the development of novel approaches to treat and control liver fibrosis caused by S. japonicum.
        2. JQ-1 ameliorates schistosomiasis liver granuloma in mice by suppressing male and female reproductive systems and egg development of Schistosoma japonicum
        Bingxin Dai, Miao Liu, Li Gong, Siwei Xia, Cuiping Ren, Weice Sun, Han Ding, Jijia Shen, Jiaming Tian, Pingping Wang PLoS Negl Trop Dis . 2022 Aug 9;16(8):e0010661. doi: 10.1371/journal.pntd.0010661.
        Schistosomiasis is a serious and widespread parasitic disease caused by infection with Schistosoma. Because the parasite's eggs are primarily responsible for schistosomiasis dissemination and pathogenesis, inhibiting egg production is a potential approach to control the spread and severity of the disease. The bromodomain and extra-terminal (BET) proteins represent promising targets for the development of epigenetic drugs against Schistosoma. JQ-1 is a selective inhibitor of the BET protein family. In the present study, JQ-1 was applied to S. japonicum in vitro. By using laser confocal scanning microscopy and EdU incorporation assays, we showed that application of JQ-1 to worms in vitro affected egg laying and the development of both the male and female reproductive systems. JQ-1 also inhibited the expression of the reproductive-related genes SjPlk1 and SjNanos1 in S. japonicum. Mice infected with S. japonicum were treated with JQ-1 during egg granuloma formation. JQ-1 treatment significantly reduced the size of the liver granulomas and levels of serum alanine aminotransferase and aspartate aminotransferase in mice and suppressed both egg laying and the development of male and female S. japonicum reproductive systems in vivo. Moreover, the mRNA expression levels of some proinflammatory cytokines were decreased in the parasites. Our findings suggest that JQ-1 treatment attenuates S. japonicum egg-induced hepatic granuloma due at least in part to suppressing the development of the reproductive system and egg production of S. japonicum. These findings further suggest that JQ-1 or other BET inhibitors warrant additional study as a new approach for the treatment or prevention of schistosomiasis.
        3. Microbial transformation of diosgenin to diosgenone by Wickerhamomyces anomalus JQ-1 obtained from Naxi traditional Jiu Qu
        Yun He, Aizhong Liu, Lixin Yang, Bayi Lang, Yanqiang Zhao, Liangqun Li, Manfred Shaowu Meng, Yuying Xie Bioorg Chem . 2020 Jan;95:103508. doi: 10.1016/j.bioorg.2019.103508.
        Diosgenone [(20S,22R,25R)-spirost-4-en-3-one, C27H40O3] has been considered as a potential therapeutic alternative remedy for malaria. An efficient and economical approach of microbial transformation with diosgenin to diosgenone by the yeast strain Wickerhamomyces anomalus JQ-1 from Naxi traditional Jiu Qu was developed in this study. Chromatographic analysis confirmed that 85% of 0.1 mM diosgenin was transformed to diosgenone within 72 h. This research demonstrates that diosgenin could be converted to diosgenone through two-step pathway including 3β-hydroxyl oxidation and double bond isomerization rather than through one-step pathway, which prompted a further inference that the oxidation activity in W. anomalus JQ-1 has the same function with the Oppenauer-type oxidation which can convert diosgenin into diosgenone. Gaining specific functional strains from traditional fermented products will be a potential direction and ethnobotanical researches could provide helps with discovery and utilization of microbial resources.
    • Preparing Stock Solutions
      • ConcentrationVolumeMass1 mg5 mg10 mg
        1 mM2.19 mL10.94 mL21.88 mL
        5 mM0.44 mL2.19 mL4.38 mL
        10 mM0.22 mL1.09 mL2.19 mL
        50 mM0.04 mL0.22 mL0.44 mL
Bio Calculators
Stock concentration: *
Desired final volume: *
Desired concentration: *


* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
Related Products
BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.

  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
  • Email:
Inquiry Basket